-
1
-
-
23744514591
-
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice
-
1 McMurray, J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, F.D., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. Eur J Heart Fail 7 (2005), 710–721.
-
(2005)
Eur J Heart Fail
, vol.7
, pp. 710-721
-
-
McMurray, J.1
Cohen-Solal, A.2
Dietz, R.3
Eichhorn, E.4
Erhardt, L.5
Hobbs, F.D.6
-
2
-
-
2442479695
-
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
-
2 Bristow, M.R., Saxon, L.A., Boehmer, J., Krueger, S., Kass, D.A., De Marco, T., et al., Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004), 2140–2150.
-
(2004)
N Engl J Med
, vol.350
, pp. 2140-2150
-
-
Bristow, M.R.1
Saxon, L.A.2
Boehmer, J.3
Krueger, S.4
Kass, D.A.5
De Marco, T.6
-
3
-
-
24944519319
-
Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure
-
3 Konstam, M.A., Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 96 (2005), 867–871.
-
(2005)
Am J Cardiol
, vol.96
, pp. 867-871
-
-
Konstam, M.A.1
-
4
-
-
19344371011
-
Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications
-
4 Davila, D.F., Nunez, T.J., Oderman, R., de Davila, C.A., Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol 101 (2005), 343–346.
-
(2005)
Int J Cardiol
, vol.101
, pp. 343-346
-
-
Davila, D.F.1
Nunez, T.J.2
Oderman, R.3
de Davila, C.A.4
-
5
-
-
0041466344
-
Pre-discharge, but not admission levels of NT-proBNP predict adverse prognosis following acute left ventricular function
-
5 O'Brien, R.J., Squire, I.B., Demme, B., Davies, J.E., Ng, L.L., Pre-discharge, but not admission levels of NT-proBNP predict adverse prognosis following acute left ventricular function. Eur J Heart Fail 5 (2003), 499–506.
-
(2003)
Eur J Heart Fail
, vol.5
, pp. 499-506
-
-
O'Brien, R.J.1
Squire, I.B.2
Demme, B.3
Davies, J.E.4
Ng, L.L.5
-
6
-
-
0037432301
-
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial
-
6 Anand, I.S., Fisher, L.D., Chiang, Y.-T., Latini, R., Masson, S., Maggioni, A.P., et al., Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial. Circulation 107 (2003), 1278–1283.
-
(2003)
Circulation
, vol.107
, pp. 1278-1283
-
-
Anand, I.S.1
Fisher, L.D.2
Chiang, Y.-T.3
Latini, R.4
Masson, S.5
Maggioni, A.P.6
-
7
-
-
34547609651
-
Serial biomarker measurements in ambulatory patients with chronic heart failure
-
7 Miller, W.L., Hartman, K.A., Burritt, M.F., Grill, D.E., Rodeheffer, R.J., Burnett, J.C. Jr., et al. Serial biomarker measurements in ambulatory patients with chronic heart failure. Circulation 116 (2007), 249–257.
-
(2007)
Circulation
, vol.116
, pp. 249-257
-
-
Miller, W.L.1
Hartman, K.A.2
Burritt, M.F.3
Grill, D.E.4
Rodeheffer, R.J.5
Burnett, J.C.6
-
8
-
-
2542492890
-
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial echocardiographic data
-
8 Wong, M., Staszewsky, L., Latini, R., Barlera, S., Glazer, R., Aknay, N., et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial echocardiographic data. J Am Coll Cardiol 43 (2004), 2022–2027.
-
(2004)
J Am Coll Cardiol
, vol.43
, pp. 2022-2027
-
-
Wong, M.1
Staszewsky, L.2
Latini, R.3
Barlera, S.4
Glazer, R.5
Aknay, N.6
-
9
-
-
84885842429
-
2013 ACCF/AHA guideline for the management of heart failure: executive summary
-
e240–327
-
9 Yancy, C.W., Jessup, M., Bozkhurt, B., Butler, J., Casey, D.E. Jr., Drazner, M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary. Circulation 128 (2013), 1810–1852 e240–327.
-
(2013)
Circulation
, vol.128
, pp. 1810-1852
-
-
Yancy, C.W.1
Jessup, M.2
Bozkhurt, B.3
Butler, J.4
Casey, D.E.5
Drazner, M.H.6
-
10
-
-
84892415130
-
Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification
-
10 Bayes-Genis, A., de Antonio, M., Vila, J., Penafiel, J., Galan, A., Barallat, J., et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification. J Am Coll Cardiol 63 (2014), 158–166.
-
(2014)
J Am Coll Cardiol
, vol.63
, pp. 158-166
-
-
Bayes-Genis, A.1
de Antonio, M.2
Vila, J.3
Penafiel, J.4
Galan, A.5
Barallat, J.6
-
11
-
-
77951206972
-
Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure
-
11 Christenson, R.H., Duh, S.-H., Wu, A.H., Smith, A., Abel, G., deFilippi, C.R., et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 43 (2010), 683–690.
-
(2010)
Clin Biochem
, vol.43
, pp. 683-690
-
-
Christenson, R.H.1
Duh, S.-H.2
Wu, A.H.3
Smith, A.4
Abel, G.5
deFilippi, C.R.6
-
12
-
-
70349813786
-
Analytical and clinical evaluation of novel high-sensitivity assay for measurement of soluble ST2 in human plasma. The presage ST assay
-
12 Dieplinger, B., Januzzi, J.L., Steinmair, M., Gabriel, C., Poelz, W., Haltmayer, M., et al. Analytical and clinical evaluation of novel high-sensitivity assay for measurement of soluble ST2 in human plasma. The presage ST assay. Clin Chim Acta 409 (2009), 33–40.
-
(2009)
Clin Chim Acta
, vol.409
, pp. 33-40
-
-
Dieplinger, B.1
Januzzi, J.L.2
Steinmair, M.3
Gabriel, C.4
Poelz, W.5
Haltmayer, M.6
-
13
-
-
84555204713
-
Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF trial
-
13 Lopez-Andres, N., Rossignot, P., Iraqi, W., Fay, R., Nuee, J., Ghio, S., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF trial. Eur J Heart Fail 14 (2012), 74–81.
-
(2012)
Eur J Heart Fail
, vol.14
, pp. 74-81
-
-
Lopez-Andres, N.1
Rossignot, P.2
Iraqi, W.3
Fay, R.4
Nuee, J.5
Ghio, S.6
-
14
-
-
1642502319
-
National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
-
14 Levey, A.S., Coresh, J., Balk, E., Kausz, A.T., Levin, A., Steffes, M.W., et al. National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139 (2003), 137–147.
-
(2003)
Ann Intern Med
, vol.139
, pp. 137-147
-
-
Levey, A.S.1
Coresh, J.2
Balk, E.3
Kausz, A.T.4
Levin, A.5
Steffes, M.W.6
-
15
-
-
41849140529
-
Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Technical report series no 80
-
Mayo Clinic Rochester, Minnesota
-
15 Kremer, W.K., Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Technical report series no 80. 2007, Mayo Clinic, Rochester, Minnesota.
-
(2007)
-
-
Kremer, W.K.1
-
16
-
-
0003570192
-
Modeling survival data: extending the Cox model
-
Springer-Verlag New York
-
16 Therneau, T.M., Grambsch, P.M., Modeling survival data: extending the Cox model. 2000, Springer-Verlag, New York.
-
(2000)
-
-
Therneau, T.M.1
Grambsch, P.M.2
-
17
-
-
38849091997
-
Evaluating the added predictive ability of new markers from area under the ROC curve to reclassification and beyond
-
17 Pencina, M.J., d'Agostino, R.B. Sr., d'Agostino, R.B. Jr., Vasan, R.S., Evaluating the added predictive ability of new markers from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008), 157–172.
-
(2008)
Stat Med
, vol.27
, pp. 157-172
-
-
Pencina, M.J.1
d'Agostino, R.B.2
d'Agostino, R.B.3
Vasan, R.S.4
-
18
-
-
79960815320
-
Evaluating the incremental value of new biomarkers with integrated discrimination improvement
-
18 Kerr, K.F., McClelland, R.I., Brown, E.R., Lumley, T., Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol 174 (2011), 364–374.
-
(2011)
Am J Epidemiol
, vol.174
, pp. 364-374
-
-
Kerr, K.F.1
McClelland, R.I.2
Brown, E.R.3
Lumley, T.4
-
19
-
-
0003474999
-
SAS/STAT user's guide, version 9 edition
-
SAS Institute Cary, North Carolina
-
19 SAS Institute. SAS/STAT user's guide, version 9 edition. 2005, SAS Institute, Cary, North Carolina.
-
(2005)
-
-
-
20
-
-
84880072700
-
Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on the interpretation of test results
-
20 Wu, A.H., Wians, F., Jaffe, A., Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on the interpretation of test results. Am Heart J 165 (2013), 995–999.
-
(2013)
Am Heart J
, vol.165
, pp. 995-999
-
-
Wu, A.H.1
Wians, F.2
Jaffe, A.3
-
21
-
-
78651387589
-
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
-
21 De Boer, R.A., Lok, D.J., Jaarsma, T., van der Meer, P., Voors, A.A., Hillege, H.L., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43 (2011), 60–68.
-
(2011)
Ann Med
, vol.43
, pp. 60-68
-
-
De Boer, R.A.1
Lok, D.J.2
Jaarsma, T.3
van der Meer, P.4
Voors, A.A.5
Hillege, H.L.6
-
22
-
-
84877246724
-
Prognostic value of changes in galectin-3 levels over time in patients with heart failure (data from CORONA and COACH)
-
22 van det Velde, A.R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure (data from CORONA and COACH). Circ Heart Fail 6 (2013), 219–226.
-
(2013)
Circ Heart Fail
, vol.6
, pp. 219-226
-
-
van det Velde, A.R.1
Gullestad, L.2
Ueland, T.3
Aukrust, P.4
Guo, Y.5
Adourian, A.6
-
23
-
-
84892996801
-
Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin measurements in patients with chronic heart failure
-
23 Gaggin, H.K., Szymonifka, J., Bhardwaj, A., Belcher, A., de Berardinis, B., Motiwala, S., et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin measurements in patients with chronic heart failure. J Am Coll Cardiol HF 2 (2014), 65–72.
-
(2014)
J Am Coll Cardiol HF
, vol.2
, pp. 65-72
-
-
Gaggin, H.K.1
Szymonifka, J.2
Bhardwaj, A.3
Belcher, A.4
de Berardinis, B.5
Motiwala, S.6
-
24
-
-
84866729958
-
Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community
-
24 Ho, J.E., Liu, C., Lyass, A., Courchesne, P., Pencirna, M.J., Vasan, R.S., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60 (2012), 1249–1256.
-
(2012)
J Am Coll Cardiol
, vol.60
, pp. 1249-1256
-
-
Ho, J.E.1
Liu, C.2
Lyass, A.3
Courchesne, P.4
Pencirna, M.J.5
Vasan, R.S.6
-
25
-
-
77950230145
-
The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data form the GISSI–Heart Failure (GISSI-HF) trial
-
25 Masson, S., Latini, R., Carbonieri, E., Moretti, L., Rossi, M.G., Iricugno, S., et al., GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data form the GISSI–Heart Failure (GISSI-HF) trial. Eur J Heart Fail 12 (2010), 338–347.
-
(2010)
Eur J Heart Fail
, vol.12
, pp. 338-347
-
-
Masson, S.1
Latini, R.2
Carbonieri, E.3
Moretti, L.4
Rossi, M.G.5
Iricugno, S.6
-
26
-
-
84857111765
-
Serial measurements of mid-region pro-ANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure
-
26 Miller, W.L., Hartman, K.A., Grill, D.E., Struck, J., Bergman, A., Jaffe, A.S., Serial measurements of mid-region pro-ANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 98 (2012), 389–394.
-
(2012)
Heart
, vol.98
, pp. 389-394
-
-
Miller, W.L.1
Hartman, K.A.2
Grill, D.E.3
Struck, J.4
Bergman, A.5
Jaffe, A.S.6
-
27
-
-
84864592311
-
Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged ≥65 years with heart failure
-
27 Kop, W.J., Gottdiener, J.S., deFilippi, C.R., Barasch, E., Seliger, S.L., Jenny, N.S., et al. Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged ≥65 years with heart failure. Circ Heart Fail 5 (2012), 406–413.
-
(2012)
Circ Heart Fail
, vol.5
, pp. 406-413
-
-
Kop, W.J.1
Gottdiener, J.S.2
deFilippi, C.R.3
Barasch, E.4
Seliger, S.L.5
Jenny, N.S.6
-
28
-
-
84999076186
-
-
Biomarkers in heart failure: the importance of inconvenient details. J Eur Soc Cardiol Heart Fail, In review.
-
28 Miller WL, Jaffe AS. Biomarkers in heart failure: the importance of inconvenient details. J Eur Soc Cardiol Heart Fail, In review.
-
-
-
Miller, W.L.1
Jaffe, A.S.2
-
29
-
-
70350733579
-
Use of aldosterone antagonists in heart failure
-
29 Albert, N.M., Yancy, C.S., Liang, L., Zhao, X., Hernandez, A.F., Peterson, E.D., et al. Use of aldosterone antagonists in heart failure. JAMA 302 (2009), 1658–1665.
-
(2009)
JAMA
, vol.302
, pp. 1658-1665
-
-
Albert, N.M.1
Yancy, C.S.2
Liang, L.3
Zhao, X.4
Hernandez, A.F.5
Peterson, E.D.6
|